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BACKGROUND: Combined therapy with carfilzomib, bendamustine, and dexamethasone was evaluated in this multicenter phase 1/2 
trial conducted within the European Myeloma Network (EMN09 trial). METHODS: Sixty- three patients with relapsed/refractory multiple 
myeloma who had received ≥2 lines of prior therapy were included. The phase 1 portion of the study determined the maximum toler-
ated dose of carfilzomib with bendamustine set at 70 mg/m2 on days 1 and 8. After 8 cycles, responding patients received maintenance 
therapy with carfilzomib and dexamethasone until progression. RESULTS: On the basis of the phase 1 results, the recommended phase 2 
dose for carfilzomib was 27 mg/m2 twice weekly in weeks 1, 2, and 3. Fifty- two percent of patients achieved a partial response or better, 
and 32% reached a very good partial response or better. The clinical benefit rate was 93%. After a median follow- up of 21.9 months, the 
median progression- free survival was 11.6 months, and the median overall survival was 30.4 months. The reported grade ≥3 hematologic 
adverse events (AEs) were lymphopenia (29%), neutropenia (25%), and thrombocytopenia (22%). The main nonhematologic grade ≥3 
AEs were pneumonia, thromboembolic events (10%), cardiac AEs (8%), and hypertension (2%). CONCLUSIONS: In heavily pretreated 
patients who have relapsed/refractory multiple myeloma, combined carfilzomib, bendamustine, and dexamethasone is an effective treat-
ment option administered in the outpatient setting. Infection prophylaxis and attention to patients with cardiovascular predisposition 
are required. Cancer 2021;127:3413-3421. © 2021 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer 
Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which 
permits use and distribution in any medium, provided the original work is properly cited, the use is non- commercial and no modifications 
or adaptations are made. 
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INTRODUCTION
The survival of patients with multiple myeloma (MM) increased in the past 2 decades, with many patients now reaching 
an overall survival (OS) of 10 years.1 Despite recently introduced immunotherapeutic strategies, MM remains most often 
incurable, and options are needed for patients who relapse after the first- generation novel agents bortezomib, lenalido-
mide, and thalidomide. The recently introduced second- generation irreversible proteasome inhibitor (PI) carfilzomib was 
effective even in patients who were previously exposed and refractory to bortezomib and did not lead to peripheral neu-
ropathy (PN) because of minimal off- target activity against nonproteasomal proteases.2- 4 The drug was initially approved 
in combination with lenalidomide plus dexamethasone for relapsed and/or refractory MM (RRMM)8 and was approved 
later at a different dose combined with dexamethasone alone.5 These data provide the rationale to combine carfilzomib 
plus dexamethasone with other agents.
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Bendamustine, a bifunctional N- Lost derivate, has 
structural similarities to alkylating agents and antimetab-
olites.6 In MM, bendamustine plus prednisone was supe-
rior to melphalan plus prednisone regarding the complete 
response (CR) rate, the time to treatment failure, and 
quality of life.7 Bortezomib may act synergistically with 
alkylating agents by increasing apoptosis induced by a 
PI because of an accumulation of defective ribosomal 
products or by inhibition of DNA repair.8- 10 Although 
bortezomib- induced PN was an issue, bendamustine 
combined with bortezomib showed promising activity in 
patients with advanced MM.11- 13 Bendamustine is cur-
rently approved in Europe even for patients who have 
MM with severe renal insufficiency.
Carfilzomib is well tolerated in patients with RRMM 
and is an option in bortezomib- refractory patients with 
existing PN.14- 16 Bendamustine produces little emesis or 
hair loss.11,12 Both drugs can be given combined in an 
outpatient setting, and bendamustine is particularly ap-
pealing because many patients with advanced MM have 
received little chemotherapy. Yet, given the increased use 
of continuous lenalidomide therapy upfront, novel im-
munomodulatory drug (IMiD)- free options are needed 
that are effective in patients who previously received bor-
tezomib. This multicenter, open- label, dose- escalation 
phase 1/2 study was conducted within the European 
Myeloma Network as EMN09 to determine the maxi-
mum tolerated dose (MTD), the safety, and the efficacy 
of combined carfilzomib, bendamustine, and dexametha-
sone (KBd) in patients with RRMM.
MATERIALS AND METHODS
Patients with RRMM who had received ≥2 prior lines 
of therapy were included. Eligibility criteria were meas-
urable disease, Karnofsky performance status ≥60%, 
creatinine clearance ≥15 mL per minute, platelet count 
≥70 × 109/L (≥50 × 109/L if MM involvement in the 
bone marrow was >50%), and neutrophil count ≥1 × 
109/L. Major exclusion criteria were grade >2 PN, active 
infection with hepatitis type B, C, or HIV positivity, and 
as congestive heart failure (New York Heart Association 
class >II). Patients received electrocardiogram and echo-
cardiographic evaluations and were excluded if they had 
a left ventricular ejection fraction <40%, symptomatic 
ischemia, or uncontrolled grade ≥3 conduction system 
abnormalities. All patients provided written informed 
consent to participate in the study, which had been ap-
proved by the institutional ethics committees. The study 
was conducted with the principles of Good Clinical 
Practice in accordance with the Declaration of Helsinki 
and was registered as ClinicalTrials.gov NCT02056756 
and EudraCT number 2012- 003938- 17.
The primary objective of the phase 1 portion was to 
determine the MTD of KBd, and the primary objective 
of the phase 2 portion was to determine the rate of very 
good partial responses (VGPRs). Secondary end points 
included overall response rates, progression- free survival 
(PFS), OS, and subgroup analyses of prognostic factors. 
Response was assessed according to the International 
Myeloma Working Group criteria with the addition of a 
near- complete response (nCR).17
All patients received oral dexamethasone 20 mg on 
days 1, 2, 8, 9, 15, 16, 22, and 23. After intravenous prehy-
dration in the range from 250 to 500 mL, carfilzomib was 
administered intravenously over 30 minutes on days 1, 2, 
8, 9, 15, and 16 of a 28- day cycle. In the phase 1 portion, 
the starting dose of carfilzomib was 27 mg/m2 (on cycle 1, 
day 1 and 2 patients received only 20 mg/m2) (dose level 
0). The subsequent carfilzomib doses were planned at 36 
mg/m2 (dose level +1) and 45 mg/m2 (dose level +2) (see 
Supporting Fig. 2). Bendamustine was administered intra-
venously with a 70 mg/m2 fixed dose on days 1 and 8 of a 
28- day cycle. In the phase 2 portion, patients received KBd 
at the MTD. Treatment was given for 8 cycles, followed by 
maintenance with carfilzomib at the MTD on days 1, 2, 15, 
and 16 plus dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 
22, and 23 every 28 days until patients developed either pro-
gressive disease (PD) or intolerance (see Supporting Fig. 1).
Dose- limiting toxicities (DLTs) according to the 
National Cancer Institute Common Terminology Criteria 
of Adverse Events (CTCAE version 4.0.) were defined as: 
any nonhematologic toxicities grade ≥3, except nausea 
or vomiting responsive to symptomatic therapy, grade 4 
neutropenia ≥7 days, other grade 4 hematologic toxicities, 
febrile neutropenia (defined as grade 3 and 4 neutropenia 
with fever 38.5 °C), and/or infection requiring antibiotic 
or antifungal treatment. Initially, lymphopenia was con-
sidered a DLT, but this was amended after phase 1, and 
mandatory infectious prophylaxis was incorporated into 
the protocol. Assessment of the MTD was performed after 
completion of the second cycle and was defined as the dose 
level at which DLT was observed in one- third of patients 
(see Supporting Fig. 3). Evaluation details and statistical 
considerations are provided in the Supporting Methods.
RESULTS
Patient Characteristics
Patients with RRMM were enrolled from April 2014 
to February 2017 at 7 EMN centers in Italy and in 
Germany. Thirteen patients were included in the phase 1 
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dose- escalation portion of the study, and 50 patients were 
included in the phase 2 portion. Baseline demographics 
and disease characteristics are listed in Table 1 and illus-
trated in Supporting Figure 3. Patients were enrolled a 
median of 5.2 years after diagnosis and had received a 
median of 3 prior lines of therapy. Previous treatment was 
extensive: 75% had received autologous and 13% had 
received allogeneic hematopoietic stem- cell transplanta-
tion, 87% were exposed to a PI, and 86% were exposed 
to IMiDs (76% had received lenalidomide [60% of these 
patients were refractory], and 27% had received poma-
lidomide). None of the patients had received prior carfil-
zomib or prior CD38 monoclonal antibody treatment. 
The median age of the entire population was 66 years 
(range, 37- 79 years). Of note, 48% of evaluable patients 
had an unfavorable chromosomal profile, with t(4;14), 
del17p, or t(14;16). At data cutoff, all patients were 
evaluable for safety and response. At a median follow- up 
of 21.9 months (interquartile range, 16.6- 28.2 months), 
the median duration of treatment was 6.9 months (inter-
quartile range, 4.5- 12.4 months). Forty patients went off 
study during or after induction; the main reason was PD 
in 20 patients and adverse events (AEs) in 13 patients. 
Of the 23 patients who proceeded to maintenance ther-
apy, 19 went off protocol mainly because of PD, and 3 
 patients experienced AEs (see Supporting Fig. 3).
Phase 1 Portion
At dose level 0 (see Supporting Fig. 2), KBd was toler-
ated and effective. However, 3 of 6 patients experienced 
grade 4 lymphopenia. The best responses were 2 stringent 
CRs, 1 nCR, 2 partial responses (PRs), and 1 stable dis-
ease. In the absence of other significant toxicities and after 
discussion with the Independent Data Safety Monitoring 
Committee, the protocol was amended, and grade 4 lym-
phopenia was not considered a DLT. At dose level +1, with 
the carfilzomib dose increased to 36 mg/m2, 1 in 3 patients 
experienced grade 4 thrombocytopenia and grade 3 febrile 
neutropenia. Therefore, 3 additional patients were enrolled 
at dose level +1; 1 patient experienced PD after cycle 1 and 
went off study before being evaluated for the occurrence of 
DLTs (evaluation was planned during the first 2 cycles), 
so 1 additional patient was included at this dose level. In 
1 patient, pneumonia classified as grade 3 was noted. The 
MTD was then defined at dose level +1. With better tol-
erability and seemingly equal clinical efficacy, phase 2 was 
conducted at dose level 0, leading to a total of 50 patients 
treated at this dose level (see Supporting Fig. 3).
Efficacy
Fifty- six of the 63 patients responded by a decrease in M 
protein (Fig. 1). In an intention- to- treat analysis, 52% of 
patients had at least a PR (≥PR), 32% had at least a VGPR 
(≥VGPR), and 17% had a CR or an nCR (Table 2). 
Among the 23 patients who responded and were eligible 
to receive maintenance treatment on 2 consecutive days 
with carfilzomib and dexamethasone, the ≥VGPR rate 
was 61%, and the ≥nCR rate was 35%.
The median PFS was 11.6 months (95% CI, 7.9- 15.3 
months) (Fig. 2A), and the median OS was 30.4 months 
(95% CI, 20.5 months to not reached) (Fig. 2B). The PFS 
was significantly better for patients who had standard- risk 
chromosomal abnormalities compared with those who had 
TABLE 1. Patient Characteristics
Characteristic No. of Patients (%)
Age, y











High riskb 22 (48)




Not available 2 (3)
Disease status
Primary refractory 3 (5)
Relapsed 41 (65)
Relapsed and refractory 19 (30)
Time from diagnosis to study entry: Median  
[IQR], y
5.2 [2.7- 8.2]













Abbreviations: ASCT, autologous stem cell transplantation; IQR, interquartile 
range; mFISH, multicolor fluorescent in situ hybridization.
aValues indicate the proportion of patients who had available FISH data (n = 
46).
bHigh- risk disease includes deletion 17p [del(17p)], or translocation (4;14) 
[t(4;14)], or translocation (14;16) [t(14;16)].
cThe proportions of those with refractory disease were based on the number 
of patients who received the drug.
dSeventeen patients received pomalidomide.
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high- risk characteristics (median, 19.6 vs 7.9 months; haz-
ard ratio, 0.43; 95% CI, 0.21- 0.88; P = .021). Although 
the subgroup analysis was limited by the small sample size, 
patients who had a poor prognosis with deletion 17p (n = 
14) still reached a PFS of 9.4 months. Similarly, OS was 
significantly improved in patients who had standard- risk 
chromosomal abnormalities (18- month OS, 87% vs 52%; 
hazard ratio, 0.24; 95% CI, 0.08- 0.67; P = .007) (Fig. 3). 
No significant differences in PFS were observed between 
patients who relapsed on or were refractory to lenalido-
mide (see Supporting Fig. 4A) and those who relapsed on 
or were refractory to bortezomib (see Supporting Fig. 4B).
Safety
The relevant side effects of KBd protocol are listed in 
Table 3. Most of the toxicities occurred during induction 
and were grade 1 or 2. The most common grade 3 and 4 
toxicities during induction were hematologic, namely, lym-
phopenia, neutropenia, thrombocytopenia, and anemia. 
Twenty- seven percent of patients received granulocyte 
colony- stimulating factor at some point. Regarding grade 
3 and 4 nonhematologic toxicities/serious AEs during in-
duction, the most frequent were infections, mainly pneu-
monia (13%), which are common in patients with such 
advanced disease. Six patients developed venous throm-
boembolism (5 patients developed pulmonary embolisms, 
and 1 patient developed deep vein thrombosis), includ-
ing 2 who had a prior history of thromboembolic events. 
Furthermore, 1 patient developed hypertension (2%), 2 
had acute coronary syndrome, and 2 had atrial fibrillation 
(3%). Three patients died, including 2 who died of heart 
failure and 1 with prior grade 3 atrial fibrillation who had 
a sudden death. Overall, 5 of 63 patients had grade ≥3 
cardiac events/hypertension, and 4 of them had a prior 
medical history positive for cardiac events/hypertension.
During maintenance, most AEs were grade 1 or 2. 
The most frequent grade ≥3 toxicities were hematologic.
Overall, 19 of 63 patients required dose reductions 
during treatment. In 9 patients, the carfilzomib dose had 
to be reduced because of cardiovascular toxicity in 3 pa-
tients, infections in 2 patients, hematologic toxicity in 2 
patients, hepatic toxicity in 1 patient, and constitutional 
symptoms in 1 patient. The reasons for dexamethasone 
dose reductions were hyperglycemia, constitutional symp-
toms, and sleeping problems in 2 patients each; and hema-
tologic or cardiovascular toxicity or infection in 1 patient 
each. Only 1 patient required a bendamustine dose reduc-
tion because of hematologic toxicity.
Thirteen patients required treatment discontinua-
tion for AEs during the induction phase. Cardiovascular 
AEs occurred in 6 patients, infections and hematologic 
Figure 1. Changes in M- protein levels compared with baseline are illustrated in individual patients with multiple myeloma.
TABLE 2. Best Overall Response, N = 63









Abbreviations: CR, complete response; nCR, near complete response; PD, 
progressive disease; PR, partial response; SD, stable disease; VGPR, very 
good partial response.
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toxicity occurred in 2 patients each, and hemorrhagic event 
and seizure occurred in 1 patient each. Only 3  patients 
discontinued for AEs during maintenance  (pulmonary 
problems, infection, or hematologic toxicity).
DISCUSSION
In recent years, the treatment armamentarium for pa-
tients with RRMM has increased. First- line treatments 
for both transplantation- eligible and transplantation- 
ineligible patients now often contain bortezomib and/
or lenalidomide and may already include monoclonal 
antibodies. If not given as first- line treatment, these 
regimens are then frequently administered as second- 
line treatment. Therefore, most patients with MM in 
the first- line or second- line setting have been exposed 
or are refractory to IMIDs, PIs, and monoclonal anti-
bodies. Because lenalidomide is commonly given until 
progression, effective treatment of IMiD- refractory pa-
tients is currently difficult. In addition, toxicities devel-
oped with prior therapies are generally an issue at the 
time of relapse. One of the most frequent side effects 
related to bortezomib is PN.18 The new PI carfilzomib 
avoids additional PN2 and proved to be efficient in pa-
tients who relapsed on or were relapsed/refractory to 
bortezomib or lenalidomide.2,5 Even in later disease 
stages, patients may not have been exposed to much con-
ventional chemotherapy. A randomized study recently 
demonstrated a trend toward better PFS when cyclo-
phosphamide was added to carfilzomib and dexametha-
sone.19 Bendamustine may be considered because it is 
well tolerated, induces high rates of DNA double- strand 
breaks, and has documented activity in MM.11,12 In vitro, 
a combination of PI and chemotherapy creates synergis-
tic effects.8,10 A phase 3 study in patients with untreated 
Figure 2. (A) Progression- free survival (PFS) and (B) overall survival (OS) are illustrated in the overall population of enrolled 
patients.
A B
Figure 3. (A) Progression- free survival and (B) overall survival are illustrated in patients with standard- risk versus high- risk multiple 
myeloma according to chromosomal abnormalities.
A B
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MM established the superiority of bendamustine to mel-
phalan,7 and bendamustine- bortezomib combinations 
were efficacious and well tolerated in this setting, includ-
ing patients who had renal impairment.14,20 However, 
because many patients already had received bortezomib 
during front- line therapy,11,13 increased PN was an issue. 
With effective supportive therapy available,21,22 a rea-
sonable quality of life is achievable even in patients with 
TABLE 3. Main Types of Treatment- Related Adverse Events
Category
No. of Events (%)
Induction, n = 63 Maintenance, n = 23
Grade 1- 2 Grade 3- 4 and SAE Grade 5 Grade 1- 2
Grade 3- 4 
and SAE
Hematologic
Lymphocytopenia — 18 (29)a — 1 (4) 4 (17)
Neutropenia 4 (6) 16 (25) — 1 (4) 1 (4)
Thrombocytopenia 9 (14) 14 (22) a — 1 (4) 1 (4)
Anemia 11 (17) 11 (17) — — — 
Infections
Pneumonia — 8 (13)b — — — 
Upper respiratory tract infection 12 (19) — — 2 (9) — 
Bronchial infection 5 (8) — — — — 
Genitourinary tract infection 4 (6) — — 2 (9) — 
CMV retinitis — — — 1 (4)
Vascular
Pulmonary embolism — 5 (8) — — — 
Deep vein thrombosis 2 (3) 1 (2) — — — 
Hypertension 1 (2) 1 (2) — 2 (9) — 
Edema 8 (13) — — — — 
Cardiologic
Heart failure — — 2 (3) — — 
Acute coronary syndrome — 2 (3) — — — 
Atrial fibrillation 1 (2) 2 (3) — 1 (4) — 
Tachycardia 4 (6) — — — — 
Neurologic
Seizures — 2 (3) — — — 
Peripheral sensory neuropathy 3 (5) — — 4 (17) — 
Tremor 3 (5) — — — — 
Dizziness 6 (10) — — — — 
Myopathy 2 (3) 1 (2) — — — 
Dermatologic
Spinocellular carcinoma — 1 (2) — — — 
Alopecia 3 (5) — — — — 
Respiratory
Dyspnea 9 (14) — — — — 
Cough 6 (10) — — — — 
Worsening of COPD — — — 1 (4) — 
Gastrointestinal
Diarrhea 6 (10) — — — — 
Dysgeusia 4 (6) — — — — 
Other
Sudden death of unknown cause — — 1 (2) — — 
ALT/AST/GGT increase 9 (14) 4 (6) — 1 (4) 2 (9)
Tumor lysis syndrome — 3 (5) — — — 
Fever of unknown origin 8 (13) 2 (3) — — — 
Creatinine increase 9 (14) 1 (2) — 1 (4) 1 (4)
Asthenia/fatigue 12 (19) — — — — 
Sleeping disorders 12 (19) — — 5 (22) — 
Headache 6 (10) — — 2 (9) — 
Hyperglycemia 4 (6) 1 (2) — 2 (9) — 
Cushing syndrome 4 (6) — — 4 (17) — 
Appetite loss 4 (6) — — — — 
Cataract — — — 1 (4) 1 (4)
Abbreviations: ALT, serum alanine aminotransferase; AST, aspartate aminotransferase; CMV, cytomegalovirus; GGT, γ- glutamyl transferase; SAE: serious adverse 
event.
aOne SAE was a dose- limiting toxicity (DLT).
bTwo SAEs were DLTs.
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advanced MM. Therefore, outpatient therapy with little 
additional sequelae should be the goal.
When studied with carfilzomib, bendamustine was 
set at a fixed dose of 70 mg/m2, which was in the range 
previously identified as efficient in other combination 
therapies for MM.11,13,23 The schedule with application 
on days 1 and 8 of a cycle provides increased individual 
flexibility and, at this dose level, may add to excellent 
gastrointestinal tolerability. Several carfilzomib doses and 
schedules have been tested and administered.2,14,24- 26 
However, in combination therapies, the optimal carfil-
zomib dose depends on the partner drug. In combina-
tion with bendamustine in the patient population with 
advanced disease treated here, the hematologic toxicities 
and infections observed when the carfilzomib dose was 
stepped up to 36 mg/m2 led to retention of the initial 
dose of 27 mg/m2 twice weekly for the subsequent phase 
2 portion of the study. This choice is supported by the im-
pressive responses already observed at this dose level used 
in other carfilzomib combinations in the relapse setting.14 
When administered with dexamethasone as a doublet reg-
imen, carfilzomib at a dose of 70 mg/m2 once weekly re-
cently proved to be superior to 27 mg/m2 twice weekly.27 
A limitation of our trial is the use of twice- weekly carfilzo-
mib, but a convenient schedule with once- weekly appli-
cation should be possible. KBd given this way in younger 
or less pretreated patients may allow a more intense 1- day 
carfilzomib dosing.
Of note, the patients receiving KBd were not only 
heavily pretreated, but a considerable portion (25%) also 
was aged >70 years. KBd did not lead to vomiting, hair 
loss, or, importantly, additional or severe PN. Because 
toxicities remaining from a prior regimen are a significant 
selection factor for subsequent therapy,28 this combina-
tion can be applied in the large group of patients with 
prior PN. Remarkably, renal toxicity was not observed 
in this study, although patients with moderate renal im-
pairment could participate. Although not formally tested 
here, renal impairment should not be a restriction.29- 31 
Cardiac events and hypertension are known to be asso-
ciated with carfilzomib and dexamethasone.32,33 In our 
study, 4 of 6 patients with cardiac events/hypertension 
had prior cardiac events/hypertension, and 2 of 6 patients 
had prior thrombosis. Clearly, this side- effect spectrum 
requires attention, the use of antithrombotic prophylaxis 
may be considered, and the risk/benefit must be carefully 
evaluated in patients who have a medical history of car-
diovascular events.32,33 Both bendamustine and carfil-
zomib may lead to severe lymphopenia in these already 
immunocompromised patients. This is why, in addition 
to herpes virus prophylaxis, prophylactic antibiotics such 
as cotrimoxazole were mandatory. Immunoglobulin sub-
stitutions would be advisable in patients with secondary 
immunodeficiency.
In the EMN09 study, KBd was received >5 years 
after initial diagnosis by almost one- half of the patient 
population beyond the third line of treatment. The ob-
served ≥VGPR rate was remarkable. Responses were also 
rapid, which is of benefit in these relapsing patients. The 
depth of responses and the PFS of 11.6 months with 
KBd at this disease stage compares favorably with other 
regimens, including bortezomib- containing combina-
tions12,13,34 and also some carfilzomib- containing35- 37 
and/or pomalidomide- containing38,39 3- drug regimens. 
Even better results may be achievable with CD38 mono-
clonal antibodies added to carfilzomib earlier in the dis-
ease course. Although KBd may also allow combination 
with antibodies, it has to be acknowledged that at least 
CD38 antibody combinations will be soon less appeal-
ing with more frequent use of antibodies with this spec-
ificity upfront.40- 42 The use of chemotherapeutic agents, 
such as cyclophosphamide or bendamustine, in RRMM 
is supported by studies in combination with IMiDs and 
PIs.23,43- 45 Combinations that include carfilzomib plus 
chemotherapy may be options at the time of relapse, pro-
vided that these agents were not received before. At the 
time of relapse, the KBd combination may be an active, 
outpatient treatment option for many patients who have 
RRMM with little limitations because of comorbidities 
other than cardiovascular impairment. The combination 
partner bendamustine is well tolerated and effective at the 
dose applied here.7,46 Since it has become generic, in many 
countries, the KBd combination may come at a competi-
tive price, offering a reasonable alternative in the context 
of an incurable disease, in which multiple lines of therapy 
are needed— often also causing a significant  financial bur-
den.47,48 It remains to be determined whether currently 
introduced treatment strategies, including immunother-
apy with bispecific antibodies or chimeric antigen recep-
tor T cells, will change this perspective.
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